MIAMI--(BUSINESS WIRE)--Jan. 25, 2006--DOR BioPharma, Inc. (AMEX:DOR) (“DOR”, or the “Company”) today announced that it has successfully completed the second development milestone for its ricin vaccine, called RiVax(TM), under the Challenge Grant previously awarded to DOR in September 2004 by the National Institute of Allergy and Infectious Diseases (NIAID), a unit of the National Institutes of Health. For the second milestone, the Company has completed the development of a process for large-scale manufacture of the key vaccine ingredient consisting of a modified ricin toxin subunit protein. In addition, supplementary characterization and formulation objectives have been achieved.
